← Leaderboards
Funda Meric-Bernstam
University Of Texas Md Anderson Can Ctr
$12,297,463
Attributed
$28,255,177
Total exposure
13
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$54,833,989 · 15
By mechanism
UM1$32,271,091 · 3
U54$8,953,772 · 3
T32$6,469,868 · 1
R01$2,886,182 · 2
U01$2,586,009 · 2
R21$920,050 · 2
Top collaborators
- James C Yao16 shared
- S Gail Eckhardt12 shared
- Jack Roth9 shared
- Jennifer A. Wargo6 shared
- Vicki Suzanne Klimberg4 shared
- John Sarantopoulos4 shared
- Elmer V Bernstam3 shared
- Anna Capasso3 shared
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- Robert C Bast$38,086,401
- Elizabeth L Travis$5,557,622
- Patricia Ann Thompson-Carino$8,608,763
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorClinical TrialsMolecularResponsePathway InteractionsResistanceLeadMalignant NeoplasmsBaseResearch PersonnelUniversitiesMutationPharmaceutical PreparationsTargeted TreatmentTargeted AgentInstitutionMolecular ProfilingUniversity Of Texas M D Anderson Cancer CenterBiological MarkersTranslatingPre-ClinicalTexasReportingGenomics
Grant awards (74)
Center for Clinical and Translational Sciences$5,479,769
UM1 · FY2025 · TR
Texas EXperimental Cancer Therapeutics Network - TEX CTN$1,679,285
UM1 · FY2025 · CA · contact PI
Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold$580,663
R01 · FY2025 · CA
15 Developmental Therapeutics$24,690
P30 · FY2025 · CA · contact PI
Center for Clinical and Translational Sciences$5,707,763
UM1 · FY2024 · TR
Texas EXperimental Cancer Therapeutics Network - TEX CTN$1,679,285
UM1 · FY2024 · CA · contact PI
A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC)$580,861
U01 · FY2024 · CA
Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold$551,629
R01 · FY2024 · CA
15 Developmental Therapeutics$23,220
P30 · FY2024 · CA · contact PI
Texas EXperimental Cancer Therapeutics Network - TEX CTN$1,952,013
UM1 · FY2023 · CA · contact PI
Training of Academic Surgical Oncologists$625,531
T32 · FY2023 · CA
A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC)$592,634
U01 · FY2023 · CA
Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold$567,912
R01 · FY2023 · CA
15 Developmental Therapeutics$18,707
P30 · FY2023 · CA · contact PI
University of Texas PDX Development and Trial Center$557,633
U54 · FY2022 · CA
Training of Academic Surgical Oncologists$500,388
T32 · FY2022 · CA
A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC)$448,905
U01 · FY2022 · CA
University of Texas PDX Development and Trial Center$199,970
U54 · FY2022 · CA
Research Project 3: Optimizing DNA damage repair-targeted combination therapy$107,662
U54 · FY2022 · CA · contact PI
University of Texas PDX Development and Trial Center$1,259,703
U54 · FY2021 · CA
Training of Academic Surgical Oncologists$604,022
T32 · FY2021 · CA · contact PI
Research Project 3: Optimizing DNA damage repair-targeted combination therapy$218,062
U54 · FY2021 · CA · contact PI
Texas EXperimental Cancer Therapeutics Network - TEX CTN$5,697,447
UM1 · FY2020 · CA · contact PI
University of Texas PDX Development and Trial Center$1,280,843
U54 · FY2020 · CA
Training of Academic Surgical Oncologists$386,192
T32 · FY2020 · CA · contact PI
Research Project 3: Optimizing DNA damage repair-targeted combination therapy$222,813
U54 · FY2020 · CA · contact PI
Evaluating drug combinations, efficacy and adaptive feedback in KRAS inhibition$120,000
U54 · FY2020 · CA
University of Texas PDX Development and Trial Center$1,447,508
U54 · FY2019 · CA
Southwest Early Clinical Trials Consortium$1,029,321
UM1 · FY2019 · CA · contact PI
Training of Academic Surgical Oncologists$417,517
T32 · FY2019 · CA · contact PI
Southwest Early Clinical Trials Consortium$320,000
UM1 · FY2019 · CA · contact PI
Research Project 3: Optimizing DNA damage repair-targeted combination therapy$250,510
U54 · FY2019 · CA · contact PI
Southwest Early Clinical Trials Consortium$120,746
UM1 · FY2019 · CA · contact PI
University of Texas PDX Development and Trial Center$60,000
U54 · FY2019 · CA
Research Project 3: Optimizing DNA damage repair-targeted combination therapy$8,571
U54 · FY2019 · CA · contact PI
Admin-Core-001$2,167,090
UM1 · FY2018 · CA · contact PI
Southwest Early Clinical Trials Consortium$2,167,090
UM1 · FY2018 · CA · contact PI
Training of Academic Surgical Oncologists$549,923
T32 · FY2018 · CA · contact PI
University of Texas PDX Development and Trial Center$175,000
U54 · FY2018 · CA
University of Texas PDX Development and Trial Center$2,561,686
U54 · FY2017 · CA
Training of Academic Surgical Oncologists$530,836
T32 · FY2017 · CA · contact PI
Research Project 3: Optimizing DNA damage repair-targeted combination therapy$483,811
U54 · FY2017 · CA · contact PI
Southwest Early Clinical Trials Consortium$300,000
UM1 · FY2017 · CA · contact PI
Southwest Early Clinical Trials Consortium$148,709
UM1 · FY2017 · CA · contact PI
Southwest Early Clinical Trials - Phase 2 Consortium$759,923
UM1 · FY2016 · CA · contact PI
Southwest Early Clinical Trials Consortium$749,998
UM1 · FY2016 · CA · contact PI
Training of Academic Surgical Oncologists$471,923
T32 · FY2016 · CA · contact PI
Southwest Early Clinical Trials Consortium$443,704
UM1 · FY2016 · CA · contact PI
Southwest Early Clinical Trials Consortium$918,950
UM1 · FY2015 · CA · contact PI
Training of Academic Surgical Oncologists$391,018
T32 · FY2015 · CA · contact PI
Informatics to enable routine personalized cancer therapy$316,190
U01 · FY2015 · CA
Southwest Early Clinical Trials Consortium$949,998
UM1 · FY2014 · CA · contact PI
Training of Academic Surgical Oncologists$417,958
T32 · FY2014 · CA · contact PI
Informatics to enable routine personalized cancer therapy$312,379
U01 · FY2014 · CA
Training of Academic Surgical Oncologists$467,865
T32 · FY2013 · CA · contact PI
Informatics to enable routine personalized cancer therapy$335,040
U01 · FY2013 · CA
Molecular predictors of post-mastectomy breast cancer loco-regional recurrence$222,454
R21 · FY2013 · CA
Training of Academic Surgical Oncologists$350,884
T32 · FY2012 · CA · contact PI
Akt Inhibitor MK-2206 for Breast Cancers with a PIK3CA Mutation and/or PTEN loss$262,015
R21 · FY2012 · CA · contact PI
Molecular predictors of post-mastectomy breast cancer loco-regional recurrence$144,821
R21 · FY2012 · CA
Training of Academic Surgical Oncologists$424,044
T32 · FY2011 · CA · contact PI
Akt Inhibitor MK-2206 for Breast Cancers with a PIK3CA Mutation and/or PTEN loss$290,760
R21 · FY2011 · CA · contact PI
Training of Academic Surgical Oncologists$331,767
T32 · FY2010 · CA · contact PI
Targeting mTOR for Cancer Therapy$233,253
R01 · FY2009 · CA · contact PI
Targeting mTOR for Cancer Therapy$233,253
R01 · FY2008 · CA · contact PI
Targeting mTOR for Cancer Therapy$233,253
R01 · FY2007 · CA · contact PI
Targeting mTOR for Cancer Therapy$240,219
R01 · FY2006 · CA · contact PI
Role of Nuclear Tyrosine Rak in Breast Cancer$68,040
K08 · FY2006 · CA · contact PI
Targeting mTOR for Cancer Therapy$246,000
R01 · FY2005 · CA
Role of Nuclear Tyrosine Rak in Breast Cancer$136,080
K08 · FY2005 · CA
Role of Nuclear Tyrosine Rak in Breast Cancer$136,080
K08 · FY2004 · CA
Role of Nuclear Tyrosine Rak in Breast Cancer$136,080
K08 · FY2003 · CA
Role of Nuclear Tyrosine Rak in Breast Cancer$68,040
K08 · FY2002 · CA
Role of Nuclear Tyrosine Rak in Breast Cancer$136,080
K08 · FY2001 · CA